Episode 68: Criticism and Credence to Medical Writing with Marielle Fares and Tom Lang

Marielle Fare & Tom Lang

Episode 68: Criticism and Credence to Medical Writing with Marielle Fares and Tom Lang

Chadi welcomes two experienced medical writers, Marielle Fares and Tom Lang, to explain what “medical writing” entails and who the intended audience is, the difference between regulatory and medical education writing as well as patient education and scientific publications, how medical projects come in and what types of instructions and materials medical writers are given, the ins-and-outs of the revision process, what it means when medical writers are listed in the acknowledgments of published clinical research, and many more points of interest.

Related Resources

Subscribe to Healthcare Unfiltered

Other Episodes You May Enjoy...

Episode 223: From Lab to Statup: Dr. Simrit Parmar on Launching Cellenkos

Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous

Read More

Episode 222: Language Matters: A Patient Perspective

Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those

Read More

Episode 221: Major Progress in Adjuvant Renal Cell Carcinoma

Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease

Read More